Humana (NYSE:HUM) Price Target Raised to $300.00

Humana (NYSE:HUM) had its price target lifted by Robert W. Baird from $270.00 to $300.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a neutral rating on the insurance provider’s stock.

A number of other equities research analysts have also issued reports on the stock. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They set a “buy” rating and a $326.00 target price on the stock. Barclays increased their price objective on Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a research note on Friday, April 11th. Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. cut their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $284.90.

Humana Trading Down 7.4 %

Shares of NYSE HUM opened at $264.41 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $31.91 billion, a PE ratio of 26.57, a PEG ratio of 2.05 and a beta of 0.62. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The stock has a fifty day simple moving average of $265.75 and a 200-day simple moving average of $269.97.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts forecast that Humana will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana’s dividend payout ratio is presently 35.58%.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Dodge & Cox grew its position in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC increased its stake in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the period. Geode Capital Management LLC raised its holdings in shares of Humana by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after buying an additional 63,562 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Humana by 29.8% during the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock worth $608,348,000 after buying an additional 550,692 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.